Enzalutamide-resistant LNCaP ARF877L Mutation KI model
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.
Check out our comprehensive platform of drug-resistant animal models
Enzalutamide-resistant LNCAP AR F877L mutant KI model
Related Content
Peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages, including high specificity,...
VIEW RESOURCEPoly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those...
VIEW RESOURCE